Charles River Laboratories International, Inc.
CRL
Rang in Aktien
#1439
Charles River Laboratories International, Inc. operates as a contract research... Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Aktienkurs
$317.20
Marktkapitalisierung
$15.28B
Veränderung (1 Tag)
6.02%
Veränderung (1 Jahr)
72.26%
Land
US
Handel Charles River Laboratories International, Inc. (CRL)
Kategorie
Healthcare
KGV für Charles River Laboratories International, Inc. (CRL)
KGV zum October 2026 TTM: -62.40
Laut den neuesten Finanzberichten und dem Aktienkurs von Charles River Laboratories International, Inc. beträgt das aktuelle P/E-Verhältnis (TTM) -62.40. Am Ende des Jahres 2023 hatte das Unternehmen ein P/E von 25.52.
P/E-Verlaufsdaten für Charles River Laboratories International, Inc. von 2000 bis 2026
P/E-Verhältnis am Ende jedes Jahres
| Jahr | KGV | ändert |
|---|---|---|
| 2026 (TTM) | -62.40 | -106.77% |
| 2024 | 921.12 | 3,510.09% |
| 2023 | 25.52 | 12.05% |
| 2022 | 22.77 | -52.05% |
| 2021 | 47.49 | 38.72% |
| 2020 | 34.24 | 16.54% |
| 2019 | 29.38 | 24.15% |
| 2018 | 23.66 | -43.83% |
| 2017 | 42.13 | 82.02% |
| 2016 | 23.14 | -7.19% |
| 2015 | 24.94 | 5.40% |
| 2014 | 23.66 | -4.44% |
| 2013 | 24.76 | 36.33% |
| 2012 | 18.16 | 43.26% |
| 2011 | 12.68 | -291.10% |
| 2010 | -6.63 | -135.24% |
| 2009 | 18.83 | -683.66% |
| 2008 | -3.23 | -111.25% |
| 2007 | 28.67 | -153.70% |
| 2006 | -53.40 | -357.08% |
| 2005 | 20.77 | -19.23% |
| 2004 | 25.71 | 34.65% |
| 2003 | 19.10 | -44.07% |
| 2002 | 34.14 | -13.64% |
| 2001 | 39.53 | -157.77% |
| 2000 | -68.44 | 0.00% |
P/E-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/E Ratio | P/E Ratio-Differenz | Land |
|---|---|---|---|
| 36.15 | -157.94% |
US
|
|
| 39.77 | -163.74% |
US
|
|
| -290.26 | 365.18% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -154.79% |
US
|
Wie liest man ein P/E Ratio?
Das Kurs-Gewinn-Verhältnis (P/E Ratio) misst das Verhältnis zwischen dem Aktienkurs eines Unternehmens und seinem Gewinn pro Aktie.
Ein niedriges, aber positives P/E weist auf ein Unternehmen hin, das hohe Gewinne im Verhältnis zur aktuellen Bewertung erzielt und möglicherweise unterbewertet ist. Ein Unternehmen mit einem hohen negativen (nahe 0) P/E macht hohe Verluste im Verhältnis zur Bewertung.
Unternehmen mit einem P/E über 30 oder negativ werden allgemein als "Wachstumsaktien" betrachtet, was bedeutet, dass Investoren erwarten, dass das Unternehmen in Zukunft wächst oder profitabel wird.
Unternehmen mit einem positiven P/E unter 10 gelten im Allgemeinen als "Value-Aktien", was bedeutet, dass das Unternehmen bereits sehr profitabel ist, aber in Zukunft wahrscheinlich kein starkes Wachstum aufweisen wird.